Development Plan for Evorpacept
A Synergistic Approach to Cancer Treatment
We are pursuing a robust development plan for evorpacept across a breadth of indications in solid and hematologic cancers with multiple combination partners.
| Program | Modality/ |
Indication |
Phase
IND Enabling
Phase 1
Phase 2
Phase 3
|
Fast Track |
|---|---|---|---|---|
| Evorpacept Programs | ||||
|
ASPEN-06
Evorpacept, Herceptin, CYRAMZA® + Paclitaxel
|
Anti-Cancer Antibodies
|
2L or 3L Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction
|
Phase 2
|
|
|
ASPEN-03
Evorpacept + KEYTRUDA®²
|
Checkpoint Inhibitors
|
1L PD-L1 Positive Advanced HNSCC (Head and Neck Squamous Cell Carcinoma)
|
Phase 2
|
|
|
ASPEN-04
Evorpacept, KEYTRUDA®, 5FU + Platinum²
|
Checkpoint Inhibitors
|
1L Advanced HNSCC (Head and Neck Squamous Cell Carcinoma)
|
Phase 2
|
|
|
ASPEN-07
Evorpacept + PADCEV®
|
ADCs
|
Urothelial Cancer
|
Phase 1
|
Not fast track
|
|
Zanidatamab³ + Evorpacept
|
ADCs
|
HER2-Expressing Breast Cancer and Other Cancers
|
Phase 1
|
Not fast track
|
|
ENHERTU®⁴ (I-SPY) + Evorpacept
|
ADCs
|
HER2-Positive Breast Cancer and Metastatic Breast Cancer
|
Phase 1
|
Not fast track
|
|
SARCLISA®⁵ + Dexamethasone + Evorpacept
|
Anti-Cancer Antibodies
|
RRMM (Relapsed or Refractory Multiple Myeloma)
|
Phase 1
|
Not fast track
|
Evorpacept Programs
ASPEN-06
Evorpacept, Herceptin, CYRAMZA® + Paclitaxel
Modality/Target
Anti-Cancer Antibodies
Indication
2L or 3L Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction
Ind
P1
P2
P3
FT
Phase 2
ASPEN-03
Evorpacept + KEYTRUDA®²
Modality/Target
Checkpoint Inhibitors
Indication
1L PD-L1 Positive Advanced HNSCC (Head and Neck Squamous Cell Carcinoma)
Ind
P1
P2
P3
FT
Phase 2
ASPEN-04
Evorpacept, KEYTRUDA®, 5FU + Platinum²
Modality/Target
Checkpoint Inhibitors
Indication
1L Advanced HNSCC (Head and Neck Squamous Cell Carcinoma)
Ind
P1
P2
P3
FT
Phase 2
ASPEN-07
Evorpacept + PADCEV®
Modality/Target
ADCs
Indication
Urothelial Cancer
Ind
P1
P2
P3
FT
Phase 1
Not fast track
Zanidatamab³ + Evorpacept
Modality/Target
ADCs
Indication
HER2-Expressing Breast Cancer and Other Cancers
Ind
P1
P2
P3
FT
Phase 1
Not fast track
ENHERTU®⁴ (I-SPY) + Evorpacept
Modality/Target
ADCs
Indication
HER2-Positive Breast Cancer and Metastatic Breast Cancer
Ind
P1
P2
P3
FT
Phase 1
Not fast track
SARCLISA®⁵ + Dexamethasone + Evorpacept
Modality/Target
Anti-Cancer Antibodies
Indication
RRMM (Relapsed or Refractory Multiple Myeloma)
Ind
P1
P2
P3
FT
Phase 1
Not fast track
1. Lilly supplies CYRAMZA® for ALX Oncology’s ASPEN-06 program
2. Merck supplies KEYTRUDA® for ALX Oncology’s ASPEN-03 and ASPEN-04 programs
3. Jazz Pharmaceuticals conducts and sponsors zanidatamab clinical trial, ALX Oncology supplies evorpacept
4. Quantum Leap Healthcare Collaborative conducts and sponsors I-SPY clinical trial, ALX Oncology supplies evorpacept
5. Sanofi conducts and sponsors SARCLISA® clinical trial, ALX Oncology supplies evorpacept